Medical technology firm Gamida Cell has gained $40m in funding for its late-stage stem cell blood cancer therapy treatment, the NiCord. The product is currently undergoing phase 3 trials and is designed to allow bone marrow transplants for patients without a suitable bone marrow donor. The funding round was led by CordIn and involved pharmaceutical company Novartis, which owns more than a 15% stake in the firm.
Medical technology firm Gamida Cell has gained $40m in funding for its late-stage stem cell blood cancer therapy treatment, the NiCord. The product is currently undergoing phase 3 trials and is designed to allow bone marrow transplants for patients without a suitable bone marrow donor. The funding round was led by Shavit Capital and involved pharmaceutical company Novartis, which owns more than a 15% stake in the firm.